Hyperhomocysteinemia and low methionine stress are risk factors for central retinal venous occlusion in an Indian population

Investigative Ophthalmology and Visual Science

Volumn 48, Issue 4, 2007, Pages 1441-1446

  Narayanasamy, Angayarkanni ^a   Subramaniam, Barathi ^a   Karunakaran, Coral ^a   Ranganathan, Punitham ^a   Sivaramakrishnan, Ramakrishnan ^a   Sharma, Tarun ^a   Badrinath, Vasanthi Sengamedu ^a   Roy, Joseph ^a  

^a MEDICAL RESEARCH FOUNDATION   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; GLUTATHIONE; HOMOCYSTEINE; METHIONINE; CYSTEINE;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; CENTRAL RETINA VEIN OCCLUSION; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HYPERHOMOCYSTEINEMIA; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OXIDATIVE STRESS; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; BLOOD; CASE CONTROL STUDY; ETHNOLOGY; FEMALE; INDIA; MALE; RETINA VEIN OCCLUSION;

ADULT; CASE-CONTROL STUDIES; CYSTEINE; FEMALE; FOLIC ACID; GLUTATHIONE; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; INDIA; MALE; METHIONINE; PREVALENCE; PROSPECTIVE STUDIES; RETINAL VEIN OCCLUSION; RISK FACTORS; VITAMIN B 12;

EID: 34248363199     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.06-0905     Document Type: Article

References (52)

1. 12 in patients with coronary heart disease. Ann Nutr Metab. 2006;50:413-419.
2. Pianka P, Almog Y, Man O, Goldstein M, Sela BA, Loewenstein A. Hyperhomocysteinemia in patients with nonarteric anterior ischemic optic neuropathy: central retinal artery occlusion and central retinal vein occlusion. Ophthalmology. 2000;107:1588-1592.
3. Wenzler EM, Rademakers AJ, Boers GH, Cruysberg JR, Webers CA, Deutman AF. Hyperhomocysteine in retinal artery and retinal vein occlusion. Am J Ophthalmol. 1993;115:162-167.
4. Brown BA, Marx JL, Ward TP, et al. Homocysteine: a risk factor for retinal venous occlusive disease. Ophthalmology. 2002;109:287-290.
5. Undas A, Brozek J, Szczeklik A. Homocysteine and thrombosis: from basic science to clinical evidence. Thromb Haemost. 2005; 94:907-915.
6. Lentz R. Mechanisms of homocysteine-induced atherothrombosis. J Thromb Haemost. 2005;3:1646-1654.
7. Tyagi N, Sedoris KC, Steed M, Ovechkin AV, Moshal KS. Mechanisms of homocysteine-induced oxidative stress. Am J Physiol. 2005;289:H2649- H2656.
8. Xiaohui Z, Hong L, Haoli J, Zachary E, Brodsky S, Goligorsky MB. Effects of homocysteine on endothelial nitric oxide production. Am J Physiol. 2000;279:F671-F678.
9. Weiss N. Mechanisms of increased vascular oxidant stress in hyperhomocysteinemia and its impact on endothelial function. Curr Drug Metab. 2005;6:27-54.
10. Tsai JC, Perrella MA, Yoshizumi M, et al. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci USA. 1994;91:6369-6373.
11. Postea O, Krotz F, Henger A, Keller C, Weiss N. Stereospecific and redox-sensitive increase in monocyte adhesion to endothelial cells by homocysteine. Arterioscler Thromb Vasc Biol. 2006;26:508-513.
12. Pathophysiological consequences of homocysteine excess. J Nutr. 2006;136:1741S-1749S.
13. Selhub J. The many facets of hyperhomocysteinemia: studies from the Framingham cohorts. J Nutr. 2006;136:1726S-1730S.
14. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med. 1998;339:1042-1050.
15. Finkelstein JD. Inborn errors of sulfur-containing amino acid metabolism. J Nutr. 2006;136:1750S-1754S.
16. Lattanzio R, Sampirtro F, Ramonia A, Fattorini A, Brancato R. Moderate hyperhomocysteinemia and early-onset central retinal vein occlusion. Retina. 2006;26:65-70.
17. Sharma P, Senthilkumar RD, Brahmachari V, et al. Mining literature for a comprehensive pathway analysis: a case study for retrieval of homocysteine related genes for genetic and epigenetic studies. Lipids Health Dis. 2006;5:1:1-19.
18. Yildirim C, Yayali V, Tatlipinar S, Kaptanoglu B, Akpinar S. Hyperhomocysteinemia: a risk factor for retinal vein occlusion. Ophthalmologica. 2004;218:102-106.
19. Prisco D, Marcucci R. Retinal vein thrombosis: risk factors, pathogenesis and therapeutic approach. Pathophysiol Haemost Thromb. 2002;32:308-311.
20. Lahey JM, Kerarney JJ, Tunc M. Hypercoagulable states and central retinal vein occlusion. Curr Opin Pulm Med. 2003;9:385-392.
21. Boyd S, Owens D, Gin T, et al. Plasma homocysteine methylene tetrahydrofolate reductase C677T and factor II G2010A polymorphism, factor VIII and VWF in central retinal vein occlusion. Br J Ophthalmol. 2001;85:1313-1315.
22. Parodi MB, Di Crecchio L. Hyperhomocysteinemia in central retinal vein occlusion in young adults. Semin Ophthalmol. 2003;18: 154-159.
23. Huesgen AG. Sensitive and Reliable Amino Acid Analysis in Protein Hydrolysates using Hp1100 series HPLC. Palo Alto, CA: Hewlett Packard; 1999:1-12.
24. Arin E, Kasrussak, Phylles G, et al. Precolumn derivatisation high performance liquid chromatography method for the determination of cysteine, cysteinyl glycine: homocysteine and glutathione in plasma and cell extracts. J Chromatography B. 2001;758:207-212.
25. Linttu M. Measurement of protein thiol group and glutathione in plasma. Methods Enzymol. 1994;223:381-385.
26. Di Crecchio L, Parodi MB, Sanguinetti G, Iacono P, Ravalico G. Hyper homocysteinemia and the methylenetetrahydrofolate reductase 677C-T mutation in patients under 50 years of age affected by central retinal vein occlusion. Ophthalmology. 2004;111:940-945.
27. Chua B, Kifley A, Wong TY, Mitchell P. Homocysteine and retinal emboli the blue mountain eye study. Am J Ophthalmol. 2006;142: 322-324.
28. Chau B, Kifley A, Wong TY, Mitchell P. Homocysteine and retinal vein occlusion: population based study. Am J Ophthalmol. 2005; 139:181-182.
29. Gao W, Wang YS, Zhang P, Wang HY. Hyperhomocysteinemia and low plasma folate as risk factors for central retinal vein occlusion: a case-control study in a Chinese population. Graefes Arch Clin Exp Ophthalmol. 2006;244:1246-1249.
30. Janssen MC, den Heijer M, Cruysberg JR, Wollersheim H, Bredie SJ. Retinal vein occlusion: a form of venous thrombosis or a complication of atherosclerosis? - a meta-analysis of thrombophilic factors. Thromb Haemost. 2005;93:1021-1026.
31. Shenoy KT, Lena KB, Sali N, et al. Cardiovit Study Team. Rationale and design for the CARDIOVIT Study (Cardiovit, Atherosclerotic vascular disease and hyperhomocysteinemia: an epidemiological study in Indians, additionally evaluating the effect of Oral Vitamin supplementation). Curr Med Res Opin. 2006;22:641-648.
32. Modi M, Prabhakar S, Majumdar S, Khullar M, Lal V, Das CP. Hyperhomocysteinemia as a risk factor for ischemic stroke: an Indian scenario. Neurol India. 2005;53:297-301.
33. Kumar J, Das SK, Sharma P, Karthikeyan G, Ramakrishnan L, Sengupta S. Homocysteine levels are associated with MTHFR A1298C polymorphism in Indian population. J Hum Genet. 2005; 50:655-663.
34. 12 in urban North India. Eur J Nutr. 2002;41:68-77.
35. Refsum H, Yajnik CS, Gadkari M, et al. Hyperhomocysteinemia and elevated methylmalonic acid indicate a high prevalence of cobalamin deficiency in Asian Indians. Am J Clin Nutr. 2001;74:233-41.
36. Chandalia M, Abate N, Cabo-Chan AV, Devaraj S, Jialal I, Grundy SM. Hyper-homocysteinemia in Asian Indians living in the United States. J Clin Endocrinol Metab. 2003;88:1089-1095.
37. Carmel R, Padmaja V. Mallidi, Vinarskiy S, Brar S, Frouhar Z. Hyperhomocysteinemia and cobalamin deficiency in young Asian Indians in the United States. Am J Hematol. 2002;70:107-114.
38. Chambers JC, Ireland H, Thompson E, et al. Methylenetetrahydrofolate reductase 677 C→T mutation and coronary heart disease risk in UK Indian Asians. Arterioscler Thromb Vasc Biol. 2000;20: 2448-2452.
39. Chambers JC, Obeid OA, Refsum H, et al. Plasma homocysteine concentrations and risk of coronary heart disease in UK Indian Asian and European men. Lancet. 2000;355:523-527.
40. Brattstrom L. Vitamins as homocysteine-lowering agents. J Nutr. 1996;126:1276S-1280S.
41. 12 deficiency the long term effects of cardiovascular disease. Cardiology. 2006; 107:57-62.
42. 6 are independent of peripheral arterial occlusive disease. J Vasc Surg. 2004;39:513-516.
43. Symons JD, Rutledge JC, Simonsen U, Pattathu RA. Vascular dysfunction produced by hyperhomocysteinemia is more severe in the presence of low folate. Am J Physiol Heart. 2006;290:H181-H191.
44. 12, and thermolabile MTHFR genotype as risk factors for retinal vascular occlusive disease. Am J Ophthalmol. 2003;136:1136-1150.
45. 6 exert distinct effects on homocysteine, serine, and methionine kinetics. Am J Physiol. 2001;281:E1182-E1190.
46. Dayal S, Devlin AM, McCaw RB, et al. Cerebral vascular dysfunction in methionine synthase-deficient mice. Circulation. 2005;112: 737-744.
47. Poloshek, Fowler B, Unsold R, Lorenz B. Disturbed visual system function in methionine synthase deficiency. Graefes Arch Clin Exp Ophthalmol. 2005;243:497-500.
48. Jacobsen DW, Catanescu O, Barbato JC. Molecular targeting by homocysteine: a mechanism for vascular pathogenesis. Clin Chem Lab Med. 2005;43:1076-1083.
49. Kerkeni M, Tnani M, Chuniaud L, Miled A, Maaroufi K, Trivin F. Comparative study on in vitro effects of homocysteine thiolactone and homocysteine on HUVEC Cells: evidence for a stronger proapoptotic and proinflammative homocysteine thiolactone. Mol Cell Biochem. 2006;291:119-126.
50. Fowler B. Homocysteine: overview of biochemistry, molecular biology, and role in disease processes. Semin Vasc Med. 2005;5: 77-86.
51. Undas A, Brozek J, Szczeklik A. Homocysteine and thrombosis: from basic science to clinical evidence. Thromb Haemost. 2005; 94:907-915.
52. Bree AD, Verschuren WMM, Kromhout D, et al. Homocysteine determinants and the evidence to what extent homocysteine determines the risk of coronary heart disease. Pharmacol Rev. 2002; 599-618.